A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells-Reference-Cited by-同舟云学术

A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells

Published:2018-04-16 Issue:8 Volume:2 Page:848-858
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Kovtun Yelena¹,Jones Gregory E.¹,Adams Sharlene¹,Harvey Lauren¹,Audette Charlene A.¹,Wilhelm Alan¹,Bai Chen¹,Rui Lingyun¹,Laleau Rassol¹,Liu Fenghua¹,Ab Olga¹,Setiady Yulius¹,Yoder Nicholas C.¹,Goldmacher Victor S.¹,Chari Ravi V. J.¹,Pinkas Jan¹,Chittenden Thomas¹

Affiliation:

1. Science, Technology, and Translation, ImmunoGen, Inc, Waltham MA

Abstract

Key Points IMGN632 is a conjugate of a novel CD123-targeting antibody with a highly potent DNA alkylating payload. IMGN632 is active in preclinical models of AML with poor prognosis at concentrations far below levels that impact normal bone marrow cells.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/2/8/848/880941/advances017517.pdf

Reference48 articles.

1. Cancer statistics, 2017;Siegel;CA Cancer J Clin,2017

2. Emerging therapies for acute myeloid leukemia: translating biology into the clinic;Kavanagh;JCI Insight,2017

3. Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia;Hackl;J Hematol Oncol,2017

4. Emerging therapies for acute myeloid leukemia;Saygin;J Hematol Oncol,2017

5. Immunotherapeutic concepts to target acute myeloid leukemia: focusing on the role of monoclonal antibodies, hypomethylating agents and the leukemic microenvironment;Gbolahan;Int J Mol Sci,2017

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An enhanced intracellular delivery platform based on a distant diphtheria toxin homolog that evades pre-existing antitoxin antibodies;EMBO Molecular Medicine;2024-08-19

2. The Immunotherapy of Acute Myeloid Leukemia: A Clinical Point of View;Cancers;2024-06-27

3. Advances in Drug Delivery Systems for the Treatment of Acute Myeloid Leukemia;Small;2024-06-27

4. Homogeneous multi-payload antibody–drug conjugates;Nature Chemistry;2024-05-17

5. Current progress in chimeric antigen receptor T‐cell therapy for malignant tumors;MedComm – Future Medicine;2024-05-13